Is triple negative a prognostic factor in breast cancer?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer treatment often relies on hormone dependency and targeted therapies like Trastuzumab for HER2-positive cases.
• Triple-negative (TN) breast cancer lacks estrogen receptor (ER), progesterone receptor (PgR), and HER2 expression, leaving it without specific targeted treatments.
• Understanding the unique biological and prognostic features of TN breast cancer is crucial for developing effective interventions.

Purpose of the Study:

• To investigate the biological and prognostic characteristics of triple-negative (TN) breast cancer.
• To compare the survival outcomes of TN breast cancer patients with those of non-TN breast cancer patients.

Main Methods:

• Retrospective analysis of 1,552 primary breast cancer patients diagnosed between January 1998 and September 2006.
• Evaluation of estrogen receptor (ER), progesterone receptor (PgR), and HER2 status in all cases.
• Immunohistochemical examination of p53 overexpression and Ki67 proliferation index.

Main Results:

• Triple-negative (TN) breast cancer constituted 14.0% of the study population.
• TN tumors exhibited a high proliferation rate, high nuclear grade, and frequent p53 overexpression.
• Patients with TN breast cancer had significantly poorer disease-free survival (DFS) and overall survival (OS) post-recurrence compared to non-TN tumors.

Conclusions:

• Triple-negative (TN) breast cancer is a distinct subtype characterized by aggressive biological features and inferior survival outcomes.
• The high proliferation rate, nuclear grade, and p53 overexpression in TN breast cancer contribute to its poor prognosis.
• Development of novel therapeutic strategies is essential to improve the survival rates for patients with TN breast cancer.